New RNA shot directly into tumors could boost immune attack

NCT ID NCT06249048

Recruiting now Disease control Sponsor: Strand Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if it can shrink advanced solid tumors in about 108 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STX-001 (a self-replicating RNA that produces IL-12, injected directly into tumors) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet known. The treatment may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
HonorHealth Research and Innovation Institute
NOT_YET_RECRUITING

Scottsdale, Arizona, 85258, United States
Huntsman Cancer Institute - University of Utah
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States
Melanoma Institute Australia
RECRUITING

Wollstonecraft, Australia
NextGen Oncology
RECRUITING

Beverly Hills, California, 90212, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.